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Abstract
Background: Prevalence of immunosuppressant nonadherence in renal transplant recipients is high despite negative clinical 
outcomes associated with nonadherence. Simplification of dosing has been demonstrated to improve adherence in renal 
transplant recipients as measured through electronic monitoring and self-report.
Objective: The purpose of this study was to replicate and extend previous findings by measuring adherence with multiple 
methods in a Canadian sample.
Design: The study design was a randomized controlled medication dosing trial in adult renal transplant patients. The trial 
length was 4 months.
Setting: This study was conducted within the Solid Organ Transplant (SOT) Clinic at Vancouver General Hospital (VGH; 
Vancouver, Canada).
Patients: A total of 46 adult renal recipients (at least 1 year post-transplant) were recruited through the SOT clinic. With 
8 withdrawals, 38 individuals completed all phases of the study.
Measurements: Medication adherence was measured for a period of 4 months using multiple methods, including electronic 
monitoring (MEMS [Medication Event Monitoring System]), pharmacy refill data (medication possession ratio [MPR]), and by 
self-report using the Adherence subscale of the Transplant Effects Questionnaire (TEQ).
Methods: Participants were randomized to twice-daily (n = 19) or once-daily tacrolimus dosing (n = 19) and followed 
over a 4-month period via monthly clinic study visits. Comparisons between the treatment groups were performed using the 
Mann-Whitney U and chi-square tests, for continuous and categorical variables, respectively.
Results: As outlined in Table 3, the once-daily dosing group showed significantly better MEMS Dose Adherence (P = .001), 
whereas MEMS Timing Adherence showed a tendency toward better adherence for this group, but was not significant (P = 
.052). MEMS Days Adherent (P = .418), MPR% (P = .123), and self-reported adherence (P = .284) did not differ between 
the once- and twice-daily dosing groups when measured as continuous variables. The MPR% was significantly better for the 
once-daily dosing group when measured dichotomously but not continuously (P = .044). Notably, most of those exposed to 
once-daily dosing (63.2%) preferred this to the twice-daily regimen.
Limitations: Limitations included small sample size and short follow-up period, precluding the examination of clinical 
outcome differences.
Conclusions: Results for dose adherence replicate the finding that dose simplification increases adherence to 
immunosuppressants as measured through electronic monitoring. Such an advantage for the once-daily dosing group was 
not seen across the 2 other electronic monitoring measurement variables (days and timing adherence). This study extends 
previous research by examining adherence in once versus twice-daily dosing via prescription refill data in a Canadian sample. 
Given the gravity of potential health outcomes associated with nonadherence, although results indicate inconsistencies in 
significance testing across measurement methods, the medium to large effect sizes seen in the data favoring better adherence 
with once-daily dosing provide an indication of the potential clinical significance of these findings.
Trial registration: This study was registered with ClinicalTrials.gov (NCT01334333) on April 11, 2011.
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Abrégé 
Contexte: Bien que la non-observance du traitement immunosuppresseur soit associée à de mauvais résultats cliniques, sa 
prévalence demeure élevée chez les receveurs d’une greffe rénale. Il a été démontré qu’une posologie simplifiée améliorait 
l’observance thérapeutique mesurée par suivi électronique et auto-évaluation dans cette population.
Objectif: Cette étude visait à reproduire et à élargir les résultats d’études précédentes en mesurant par différentes méthodes 
l’observance thérapeutique dans un échantillon de patients canadiens.
Type d’étude: Un essai contrôlé à répartition aléatoire d’une durée de quatre mois examinant la posologie médicamenteuse 
d’adultes greffés rénaux.
Cadre: L’étude s’est tenue au sein de la Solid Organ Transplant Clinic (clinique SOT) du Vancouver General Hospital (VGH; 
Vancouver, Canada).
Sujets: Quarante-six greffés rénaux adultes ont été recrutés (au moins un an post-transplantation) par l’entremise de la 
clinique SOT. En raison de huit retraits, l’étude porte sur trente-huit individus ayant complété toutes les phases de l’étude.
Mesures: L’observance thérapeutique a été mesurée sur une période de quatre mois, selon différentes méthodes, notamment 
le suivi électronique (MEMS), le renouvellement des ordonnances (rapport de possession de médicaments—RPM) et l’auto-
évaluation avec la sous-échelle d’observance du Transplant Effects Questionnaire (TEQ).
Méthodologie: Les participants ont été répartis aléatoirement pour recevoir du tacrolimus deux fois par jour (n = 19) 
ou une fois par jour (n = 19) et ont été suivis pendant quatre mois au moyen de visites mensuelles à la clinique. Les 
comparaisons entre les groupes de traitement ont été effectuées par tests U de Mann-Whitney (variables continues) et tests 
de chi-deux (variables nominales).
Résultats: Comme indiqué dans le tableau 3, lorsque l’observance est mesurée par MEMS, le groupe ayant reçu une dose 
quotidienne unique a montré une observance nettement supérieure au niveau de la dose (P = 0.001), de même qu’une 
tendance vers une meilleure observance du traitement au niveau du moment, quoique cette dernière ne soit pas significative 
(P = 0.052). Le nombre de jours d’observance mesuré par MEMS (P = 0.418), le pourcentage RPM (P = 0.123) et l’observance 
auto-déclarée (P = 0.284) n’ont pas différé entre les groupes lorsque mesurés comme variables continues. Le pourcentage 
RPM était significativement plus élevé pour le groupe traité une fois par jour, lorsque mesuré de façon dichotomique, mais 
non continue (P = 0.044). La majorité des patients traités par une dose unique quotidienne (63.2%) ont préféré ce schéma 
posologique à une prise deux fois par jour.
Limites: La petite taille de l’échantillon et la courte période de suivi empêchent l’examen des différences observées dans 
les résultats cliniques.
Conclusion: Les résultats sur l’observance de la dose reproduisent la conclusion selon laquelle un dosage simplifié 
augmenterait l’observance du traitement immunosuppresseur, lorsque mesurée par MEMS. Un tel avantage pour le groupe 
recevant une dose quotidienne unique n’a pas été observé pour les deux autres variables de mesure par MEMS (observance 
en jours et du moment de la prise du médicament). La présente étude élargit les recherches antérieures en examinant 
l’observance de la posologie (une ou deux fois par jour) avec les données de renouvellement des ordonnances dans un 
échantillon canadien. Compte tenu de la gravité des effets potentiels de la non-observance thérapeutique sur la santé, et bien 
que les résultats indiquent des incohérences entre les méthodes de mesure dans la vérification des hypothèses, l’ampleur 
moyenne à grande de l’effet observé dans les données favorisant une meilleure observance à une dose unique quotidienne 
souligne l’importance clinique potentielle de ces résultats.
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What was known before
Simplification of dosing regimen has been demonstrated to 
improve immunosuppressant adherence in renal transplant 
recipients as measured through electronic monitoring and 
self-report.1-3
What this adds
The purpose of this study was to replicate these findings using 
a randomized controlled trial using multiple adherence mea-
sures within a Canadian sample. Although results replicate 
the finding that dose simplification results in better adherence 
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to immunosuppressants as measured through one specific 
electronic monitoring assessment and one measurement of 
pharmacy refill data, the advantage is not supported when 
other adherence measurement methods are used. Nonetheless, 
this study extends previous findings by showing an effect via 
analysis of prescription refill data within a Canadian sample 
and by calling attention to the potential differences between 
adherence measurement methods (even differing electronic 
measurement methods).
Introduction
A critical aspect of real-world functioning following renal 
transplantation involves how adherent individuals are to 
their medication regimens. Nonadherence to immunosup-
pressant medications post-transplant is related to increased 
morbidity and mortality and has been shown to significantly 
increase rate of graft rejection.4,5 Regardless, extant research 
has reported variable and relatively high rates of nonadher-
ence following organ transplant, with rates of up to 86% 
reported in older renal transplant recipients.6,7
Previous research suggests that medication dosing regi-
mens may be an important factor influencing medication 
adherence implementation. For instance, research with indi-
viduals receiving antihypertensive medications using elec-
tronic monitoring has shown that adherence improved (from 
59.0% to 83.6%) when thrice-daily dosing was compared 
with once-daily dosing.8 Research examining once-daily in 
comparison to twice-daily tacrolimus dosing in renal trans-
plant recipients has indicated that switching from a twice-
daily dose is safe and does not lead to significant changes in 
blood glucose, potassium, or magnesium in this group.9,10 In 
addition, in a 2-year study in renal transplant recipients, 
approximately 35% of participants indicated a preference for 
once-daily dosing.10 More recent research indicates improved 
adherence as measured via electronic monitoring in one ran-
domized controlled trial in this group.1 Nonetheless, other 
studies using self-report measures of adherence indicate 
mixed results. Two observational studies (1 cross-sectional 
and 1 prospective) indicate improved adherence for once-
daily tacrolimus.2,3 By contrast, a randomized trial (using 
self-report adherence diaries) found no difference in adher-
ence between once- and twice-daily dosing in renal trans-
plant recipients.11
In this study, we wished to further clarify the relationships 
between tacrolimus dosing schedule and implementation 
adherence (ie, the extent to which the patient’s dosing behav-
ior corresponds with the prescribed regimen)12 among renal 
transplant recipients in western Canada. Specifically, we 
aimed to determine whether previous findings of improved 
adherence for once- versus twice-daily dosing of tacrolimus 
could be replicated in a randomized controlled trial using 
multiple adherence implementation measures. Toward these 
ends, we examined not only electronic monitoring and self-
report measures of adherence but also pharmacy prescription 
refill records. To our knowledge, this is the first randomized 
controlled trial to assess adherence in these dosing regimens 
via multiple adherence measurement methods and within a 
Canadian sample. Based on previous literature focusing on 
electronic monitoring and self-report adherence measure-
ments, we hypothesized that once-daily dosing would be 
associated with increased adherence as measured by elec-
tronic monitoring. Although literature is mixed with respect 
to self-reported adherence, and nonexistent for pharmacy 
refill data, we also hypothesized that once-daily dosing 
would be associated with improved adherence as assessed 
via these methods.
Methods
Population and Setting
Participants were recruited from the Solid Organ Transplant 
(SOT) Clinic at Vancouver General Hospital (VGH) in 
Vancouver, BC, Canada. To be eligible, participants met the 
following inclusion criteria: (1) capable of giving informed 
consent; (2) no visual, hearing, or other sensory/motor 
impairments that may interfere with the testing procedures; 
(3) fluent in the English language; (4) minimum of Grade 6 
education (due to reading requirements of questionnaires); 
(5) absence of psychosis; (6) absence of acute illness (eg, 
metastatic cancer), neurological disease, and other major 
organ failure (eg, end-stage liver disease); and (7) minimum 
1 year post-transplant with a successful kidney graft and 
stable kidney functioning (estimated glomerular filtration 
rate [eGFR] above 25 mL/min per 1.73 m2). Participants 
were excluded from the study if they did not meet all of the 
above requirements.
Design and Procedure
A flowchart describing participant recruitment and participa-
tion is presented in Figure 1. Potential participants were con-
tacted using a recruitment letter that was followed up by a 
telephone call to determine their interest and schedule partici-
pation. Approximately 31% of those meeting inclusion criteria 
for the study showed interest in and were scheduled to com-
plete the study. A total of 46 individuals were enrolled in the 
study, of which 38 completed all required study visits. Barriers 
to enrollment included difficulty obtaining transportation to 
study visits, requirement for additional clinic visits over stan-
dard care, preference for non-English language, and required 
randomization of medication formulation. Reasons for with-
drawal from the study are also summarized in Figure 1.
At the initial study visit (coordinated with participants’ 
regular clinic visit), trained research assistants randomly 
assigned each of the 46 participants to receive either the 
once-daily Advagraf (tacrolimus extended release; n = 24) 
or twice-daily Prograf (tacrolimus; n = 22) tacrolimus for-
mulation using a random number generator. At this time, 
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participants also received medication counseling and 
instructions for use of the MEMS (Medication Event 
Monitoring System) caps and completed study question-
naires. Participants at the SOT Clinic routinely receive 
medications from the SOT Clinic pharmacy, which facili-
tated an immediate change in tacrolimus formulation. All 
participants received a 1-month supply of their assigned 
study medication and returned once per month for study 
appointments to refill medications and complete study 
questionnaires. A total of 5 study visits over a 4-month 
duration were completed.
All participants signed letters of informed consent and 
received Can$20.00 per study visit to offset time and travel 
expenses. Ethics boards at the University of British Columbia, 
Simon Fraser University, and Vancouver Coastal Health 
Authority approved the protocol for this study. This study is 
registered with ClinicalTrials.gov (NCT01334333).
Data Collection
Demographic information was collected from all partici-
pants during the initial study visit. This included age, sex, 
current employment status, living situation (ie, alone or 
with others), ethnicity, and level of education. In addition, 
Health and Medical History questionnaires created by our 
laboratory were completed with participants and validated 
against available medical records to provide relevant medi-
cal and transplant-related history (eg, number of renal 
transplants, type of transplant, time since transplant, eGFR 
and hemoglobin levels, and chronic kidney disease [CKD] 
G category).13,14
Medication adherence was measured using multiple 
methods. Electronic monitoring through the MEMS 6 caps 
was undertaken for the span of the 4-month study period. 
During the initial study visit, participants were taught how to 
properly open and close bottles using these caps. They were 
Figure 1. Participant recruitment flowchart.
Note. Regarding inclusion/exclusion criteria at intake, participants who indicated less than 3 of 4 preferences as “English” for speaking, reading, writing, 
and thinking on an acculturation questionnaire were considered ineligible due to language requirements for neurocognitive testing necessary for the larger 
study, of which these participants were a part; in addition, those reporting any of the abovementioned physical or mental health exclusions were ineligible. 
Not interested = participants who declined study participation due to lack of interest; Not scheduled = participants who expressed interest in the study, 
but who had scheduling conflicts and did not participate.
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instructed to take their daily (once or twice depending on 
formulation) tacrolimus dose from the MEMS cap–equipped 
bottles and to only open the cap when taking their prescribed 
medication dose. Three measurements were computed using 
the MEMS PowerView software: (1) percentage of doses 
each participant retrieved from the MEMS cap–equipped 
bottle (ie, number of doses retrieved, divided by the number 
of doses assigned during the study period, multiplied by 100; 
MEMS Dose Adherent), (2) percentage of days during the 
study period on which the correct number of doses were 
taken (ie, 1 dose/day for those in the once-daily group and 2 
doses/day for those in the twice-daily group; MEMS Days 
Adherent), and (3) percentage of doses taken within a near-
optimal interdose interval (calculated as the interval between 
bottle openings – 12 ± 3 hours or within a 9-15 hour range 
for twice-daily, and 24 ± 6 hours or within an 18-30 hour 
range for once-daily dosing15; MEMS Timing Adherent). As 
much of the extant adherence literature has examined adher-
ence dichotomously, we also computed adherence/nonadher-
ence dichotomous variables for MEMS Dose, MEMS Days, 
and MEMS Timing Adherent measures; on these dichoto-
mous measures, as patients may take fewer or more doses 
than prescribed, participants who retrieved between 90% and 
110% of doses (MEMS Dose Adherent Dichotomous) and/or 
had at least 80% accurate dosing (MEMS Days Adherent 
Dichotomous and MEMS Timing Adherent Dichotomous) 
were categorized as adherent. In all instances, similar cut-
points have been used in the transplant adherence 
literature.16
Pharmacy refill data were also collected through the SOT 
pharmacy databases and records. Data available for the study 
period were used to calculate a medication possession ratio 
(MPR), reflecting the amount of prescribed medication an 
individual obtained within a specified period compared with 
that which they should have obtained during that period. 
Medication possession ratios were multiplied by 100 to pro-
vide a continuous percentage measure of adherence (MPR%). 
A dichotomous MPR% variable (MPR% Dichotomous) was 
then also computed, for which MPRs between 90% and 
110% were considered adherent and those above or below 
this level as nonadherent, consistent with criteria previously 
used for pill count data.16
Participants also completed the Adherence subscale of the 
Transplant Effects Questionnaire (TEQ) at the end of the study 
period (TEQ Adherence) to provide a measure of self-reported 
adherence.17 This scale has 5 items related to medication 
adherence behaviors, which are endorsed on a Likert scale 
ranging from strongly agree to strongly disagree (eg, 
“Sometimes I think I do not need my anti-rejection medi-
cines”), for a score range of 5 to 25, with higher scores indicat-
ing greater adherence. Test-retest reliability of responses to the 
Adherence subscale after a 1-month interval has been found to 
be high (r = .77).17 Responses to this subscale also signifi-
cantly correlate with the Short Form Health Survey (SF-36; a 
measure of quality of life related to health),18 in renal trans-
plant recipients.19
Health literacy was examined using the Health Literacy 
Questionnaire (HLQ),20 which assesses both intrinsic and 
extrinsic facets and the social and cognitive skills associated 
with health literacy. The HLQ is a 44-item questionnaire that 
provides a multidimensional profile of health literacy. In the 
first section (23 items), items are responded to via a 4-point 
Likert scale ranging from 1 (strongly disagree) to 4 (strongly 
agree). In the second section (21 items), items are responded 
to using a 5-point Likert scale ranging from 1 (cannot do) to 
5 (very easy). To reduce the probability of Type I error and 
the number of variables, a total HLQ score (sum of scores for 
items 1-44) was computed. The total possible score ranged 
from 44 to 197, with higher scores indicating higher self-
reported health literacy.
Data Analysis
A review of the transplant adherence literature21 indicates 
that the distribution of adherence data is often highly skewed, 
and that the implications of this are often not appropriately 
considered in data analysis. With this in mind, the 
Kolmogorov-Smirnov test was used to determine whether 
our continuous adherence measurement variables were nor-
mally distributed. Results indicated nonnormal distributions 
for MEMS Dose Adherent (P < .001), MEMS Days Adherent 
(P < .001), MPR% (P < .001), and TEQ Adherence (P = 
.008). As a result, we used the Mann-Whitney U (nonpara-
metric) test to determine whether differences existed between 
the once- and twice-daily prescribed tacrolimus groups for 
these continuous measures. An independent-samples t test 
was used to examine MEMS Timing Adherent between 
groups. The chi-square test (χ)2 was used to compare cate-
gorical variables between groups.
Results
Sample Characteristics
Table 1 shows the sample characteristics. The study sample 
included significantly more men (n = 22) than women (n = 
16) across treatment groups (t[37] = 17.51, P < .001); how-
ever, sex distributions were equivalent in both groups. All 
participants were in G categories 1 to 3 of CKD based on 
eGFR levels. In total, 22 participants were assigned to the 
twice-daily tacrolimus dosing group and 24 to the once-daily 
dosing group. After accounting for participant withdrawals, 
data from 19 participants were available for each of the once- 
and twice-daily study groups (comparison of demographic 
and clinical variables between those who withdrew and those 
who completed the study was not possible as most of the 
participants who withdrew did so prior to the collection of 
this medical and demographic information).
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For baseline group characteristics and statistical compari-
sons between the study groups, see Table 1; no statistically 
significant differences were seen for demographic and base-
line illness variables examined between the study groups. In 
addition, no significant group differences were seen in scores 
on a health literacy measure nor on a self-reported adherence 
measure administered at the initial study visit (time of ran-
domization). For post-assessment comparisons of health vari-
ables between groups, see Table 2. A significant difference 
between groups was only seen for tacrolimus serum level. 
Interestingly, although tacrolimus serum levels did not differ 
at the outset of the study, those taken at the conclusion of the 
study were significantly higher in the twice-daily dosing group 
(P = .002), though both groups were within target range.
Once- Versus Twice-Daily Tacrolimus Effects on 
Measured Adherence
Table 3 shows group comparisons. With respect to continu-
ous measures, level of medication adherence significantly 
differed between once- and twice-daily tacrolimus groups as 
measured by the MEMS Dose Adherent variable (P = .001). 
The once-daily tacrolimus group had a higher mean percent-
age of adherence as determined via the number of doses 
taken during the monitoring period (mean = 102.17%, SD = 
3.99 vs mean = 95.94, SD = 9.03). Although MEMS Days 
Adherent did not significantly differ between groups, MEMS 
Timing Adherent showed a tendency toward better adher-
ence in the once-daily group (once-daily: 95.07%, twice-
daily: 89.10%; P = .052) that was not statistically significant. 
In consideration of dichotomous measures, adherence as 
measured by MPR% (MPR between 90% and 110% consid-
ered adherent) significantly differed between the once- and 
twice-daily tacrolimus groups (P = .044). In the once-daily 
group, 15 participants were considered adherent (78.95%), 
whereas in the twice-daily group 9 participants were adher-
ent (47.37%). See Table 4 for correlational analyses across 
groups; in these analyses, higher percent dose adherence 
(large effect size), timing adherence (medium to large effect 
size), and on-target MPR% (medium effect size) were also 
each significantly associated with once-daily dosing, provid-
ing additional support for the aforementioned group differ-
ences. No significant group differences were found for 
self-reported medication adherence. All other effect sizes are 
estimated to be small, with some approaching a medium 
effect size (ie, r or V = 0.3).22 With the exception of correla-
tions between MEMS Days Adherent and MEMS Timing 
Adherent with MPR% continuous variables, the 3 categories 
Table 1. Baseline Demographic and Health Characteristics by Tacrolimus Dosing Group.
Variable
Participants (N = 38)
Once-daily (n = 19) Twice-daily (n = 19)
N (%)/mean ± SD N (%)/mean ± SD
Age 52.26 ± 13.28 (range: 29-77) 52.95 ± 11.60 (range: 24-66)
Sex: male 11 (57.9) 11 (57.9)
Ethnicity
 White  7 (36.8) 11 (57.9)
 Asian  8 (42.1) 2 (10.5)
 Other  4 (21.1) 6 (31.6)
Education 14.32 ± 2.31 14.32 ± 2.28
English as a second language: yes  8 (42.1) 5 (26.3)
Living situation: Alone  3 (15.8) 5 (26.3)
Transplant > 1  2 (10.5) 1 (5.3)
Type of transplant: cadaveric  8 (42.1) 11 (57.9)
Time since transplant  7.25 ± 5.61  8.00 ± 6.61
Time on dialysis pre-transplant  2.88 ± 2.25  2.62 ± 2.56
Tacrolimus level (µg/L)  6.28 ± 1.52  6.01 ± 1.57
Hemoglobin level (g/L) 126.17 ± 18.63 135.05 ± 18.04
Estimated glomerular filtration rate level (mL/min/1.73 m2)  66.67 ± 20.10  57.00 ± 16.54
Creatinine level (µmol/L) 103.67 ± 47.59 113.37 ± 34.50
KDIGO CKD G category
 G1  3 (16.7) —
 G2 10 (55.6)  8 (42.1)
 G3  4 (22.3) 11 (57.9)
 G4 1 (5.6) —
Health Literacy Questionnaire total score 155.92 (16.81) 154.00 (14.29)
Note. KDIGO = The Kidney Disease: Improving Global Outcomes; CKD = chronic kidney disease.
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Table 2. Post-Assessment Health Characteristics by Tacrolimus Dosing Group.
Variable
Participants (N = 38)
χ2/tOnce-daily (n = 19) Twice-daily (n = 19)
N (%)/mean ± SD N (%)/mean ± SD P value
Tacrolimus (µg/L) 4.83 ± 1.44 6.20 ± 1.08 .002*
Hemoglobin (g/L) 124.11 ± 17.59 132.53 ± 18.90 .164
Estimated glomerular filtration rate (mL/min/1.73 m2) 63.94 ± 21.39 57.68 ± 19.52 .358
Creatinine (µmol/L) 107.63 ± 45.55 113.42± 34.05 .660
KDIGO CKD G category .334
 G1 2 (11.1) 1 (5.3)  
 G2 8 (44.4) 5 (26.3)  
 G3 8 (44.4) 13 (68.4)  
Note. Tacrolimus level was that obtained closest to the end of study participation. All other values were collected at the first visit post–study completion; 
t test results for continuous variables and Pearson chi-square test results for categorical variables; CKD = chronic kidney disease; KDIGO = The Kidney 
Disease: Improving Global Outcomes.
*P < .01.
Table 3. Medication Adherence Measurements by Tacrolimus Dosing Group.
Measure
Once-daily (n = 19) Twice-daily (n = 19) χ2/U r/d/V
N (%)/mean ± SD N (%)/mean ± SD P value Effect size
MEMS Dose Adherent 102.17 ± 3.99 95.94 ± 9.03 .001** 0.528
MEMS Dose Adherent (Dich) 19 (100) 16 (84.2) .071 0.293
MEMS Days Adherent 93.76 ± 3.53 89.09 ± 11.08 .418 0.135
MEMS Days Adherent (Dich) 19 (100) 16 (84.2) .071 0.293
MEMS Timing Adherent 95.07 ± 5.63 89.10 ± 11.48 .052 0.660
MEMS Timing Adherent (Dich) 19 (100) 16 (84.2) .071 0.293
MPR% 109.52 ± 13.35 106.73 ± 27.12 .123 0.253
MPR% (Dich) 15 (78.9)  9 (47.4) .044* 0.327
TEQ Adherence 20.33 ± 3.73 21.58 ± 3.52 .284 0.180
Note. N’s represent the number of participants considered adherent using each variable and %’s represent the percent of each group considered adherent 
by each measure. For MEMS Dose Adherent and MPR%, values greater than 100% were possible. Effect sizes are presented as Pearson’s r for Mann-
Whitney U tests (continuous data), Cohen’s d for the t test, and as Cramer’s V for chi-square tests (dichotomous data). For Pearson’s r and Cramer’s  
V: 0.1 = small, 0.3 = medium, 0.5 = large; for Cohen’s d: 0.2 = small, 0.5 = medium, 0.8 = large. MEMS = Medication Event Monitoring System; MPR = 
medication possession ratio; TEQ = Transplant Effects Questionnaire; dich = dichotomous.
*P < .05. **P < .01.
Table 4. Correlations Between Tacrolimus Formulation and Adherence Measures Examined.
1 2 3 4 5 6 7 8 9 10
1. Tacrolimus Formulation —  
2. MEMS Days Adherent .280 —  
3. MEMS Days Adherent (Dich) .293 .848** —  
4. MEMS Dose Adherent .417** .851** .853** —  
5. MEMS Dose Adherent (Dich) .293 .848** 1.000** .853** —  
6. MEMS Timing Adherent .321* .952** .794** .831** .794** —  
7. MEMS Timing Adherent (Dich) .293 .848** 1.000** .853** 1.000** .794** —  
8. MPR% .067 .361* .231 .313 .231 .371* .231 —  
9. MPR% (Dich) .327* .083 .181 .234 .181 –.010 .181 –.359* —  
10. TEQ Adherence –.174 –.074 –.279 –.173 –.279 –.047 –.279 –.042 .181 —
Note. MEMS = Medication Event Monitoring System; MPR = medication possession ratio; TEQ = Transplant Effects Questionnaire; dich = dichotomous.
*Correlation is significant at the .05 level (2-tailed). **Correlation is significant at the .01 level (2-tailed).
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of adherence measures (electronic, pharmacy, and self-
report) did not correlate with one another. As expected, sig-
nificant associations were demonstrated between variables 
of the same adherence category (ie, MEMS adherence vari-
ables correlated with one another as did MPR% variables).
Patient Preferences for Once- Versus Twice-Daily 
Dosing
Following completion of the study, participants were given 
the choice of continuing with or switching to the once-daily 
medication formulation. Pharmacy records indicated that 18 
of 19 (94.74%) participants randomized to the twice-daily 
regimen chose to continue with that dosing, 12 of 19 
(63.16%) who had been assigned to the once-daily regimen 
chose to continue with that dosing, whereas 7 (36.84%) 
chose to revert to twice-daily dosing. Notably, a relatively 
high percentage of those exposed to once-daily dosing in this 
study appeared to prefer this to their previous twice-daily 
regimen. Qualitatively, participants completed preference 
questionnaires following completion of the study, with many 
of those uninterested in the once-daily dosing, noting that 
they preferred twice-daily dosing due to maintaining their 
original routine, need to take other medications twice daily, 
and/or worries that changing dosing may impact health.
Discussion
Our findings provide some replication of previous research 
demonstrating that dose simplification is related to improved 
medication adherence in renal transplant participants, with 
significant differences seen between study groups specifi-
cally with respect to dose adherence and pharmacy refill 
data. By contrast, other measures of adherence examined did 
not indicate statistically significant group differences in our 
small sample. Importantly, our results extend previous 
research by comparing adherence between once- and twice-
daily tacrolimus dosing groups using multiple methods 
(electronic monitoring, pharmacy refill data, and self-report) 
in a Canadian sample, and demonstrate that dose simplifica-
tion is related to improved adherence as assessed through 
both measures of electronic monitoring (%Dose Adherence) 
and analysis of pharmacy refill data. Although other group 
differences in adherence were not supported in this study, it 
is notable that our sample was small, and as such our study 
likely lacked statistical power to detect smaller statistical dif-
ferences between groups. Our results also suggest satisfac-
tion with the simplified regimen for most of the patients who 
were randomized to once-daily dosing as demonstrated by 
the large percentage of patients who preferred to continue 
with this regimen following study completion.10 Preference 
for maintenance of twice-daily dosing was driven by interest 
in maintaining routine, requirements of other medications to 
be taken twice daily, and worries that changing dosing 
may impact health. Interestingly, although tacrolimus serum 
levels did not differ at the outset of the study, at the conclu-
sion of the study, levels were significantly higher in the 
twice-daily dosing group. Similar differences in tacrolimus 
levels have been reported in previous studies examining 
once- versus twice-daily dosing and have been unrelated to 
outcomes such as acute rejection.1
Recent research in other illness groups has proposed that 
there is no gold standard measure of medication adherence, 
and as such the use of multiple methods may provide the most 
thorough understanding of adherence difficulties.23 However, 
as seen here and in previous work, the use of multiple meth-
ods may also introduce inconsistencies.23 Discrepancies were 
observed even across electronically measured variables of 
adherence, with only MEMS Dose Adherent significantly dif-
fering between dosing groups (demonstrating a large effect), 
whereas MEMS Timing Adherent showed a tendency that 
was not statistically significant. Adherence may, thus, depend 
on the chosen measurement methods, and given the dispari-
ties between the different adherence measures examined, it 
appears prudent to better determine how each of these mea-
sures relates to specific health outcomes for renal transplant 
recipients.
Although differences in adherence seen between groups 
did not readily translate to differences in clinical blood levels 
examined (ie, hemoglobin, creatinine, tacrolimus, eGFR) in 
this study, there was only a 4-month follow-up period, and 
thus potential long-term clinical impacts of poorer adherence 
could not be captured. It is likely that a longer-term follow-
up study may reveal differences in clinical outcomes (eg, lab 
values, graft rejection, loss) associated with lower adherence 
in a twice-daily tacrolimus group and would allow further 
exploration of the relationship of various dosing errors (dos-
ing, days, timing) with outcome. Clinically, although the pre-
cise levels of nonadherence required to lead to poor outcomes 
have not yet been determined,24 even small deviations from a 
prescribed regimen have the potential to negatively impact 
the intended effect of treatment.25,26
Previous literature reporting significant differences in 
adherence between once- and twice-daily dosing of tacroli-
mus has not generally reported data that readily lend to cal-
culation of effect sizes.1-3 Nonetheless, examination of one 
study reporting no significant differences between dosing 
regimens indicated a trivial effect size for adherence (Cohen’s 
d = 0.157; calculated from data provided in original publica-
tion).11 By contrast, effect sizes for relationships tested in 
this study were small to medium, with the exception of 
MEMS Dose Adherent (large effect). Clinically, however, 
when evaluating the practical significance of effect sizes, the 
gravity of the outcome in question as well as the quality of 
the measurement should be considered.27 In the case of non-
adherence, from a practical perspective, associated compli-
cations of morbidity and potential mortality4,25 imply that 
medium (MPR% and MEMS timing adherence data) and 
large (MEMS dose Adherence data) effect sizes observed in 
this study are highly significant. This study relied on well-
Paterson et al 9
validated measures of adherence, further adding to the clini-
cal importance of our findings.
Our results did not reveal significant differences in adher-
ence between treatment groups when self-report adherence 
ratings were considered. Previous research indicates mixed 
results with respect to differences in self-reported adherence 
among those with once- versus twice-daily prescriptions.2,3,11 
Examination of effect sizes from previous research examin-
ing self-reported adherence (and those seen in this study) 
indicates that the magnitude of these differences is likely to 
be small and thus more difficult to detect in smaller samples. 
Previous research has found the prevalence of nonadherence 
as measured through self-report to be lower than that detected 
through electronic monitoring,28 possibly reflecting a lower 
sensitivity in detecting nonadherence, which may also 
explain the mixed results of studies using these measures.2,3,11 
Our review of previous studies examining self-reported 
adherence between once- and twice-daily tacrolimus dosing 
highlights the need going forward for researchers to include 
effect size data in their analyses to aid in interpretation.
Limitations of our study include a small sample size and a 
short follow-up period that precluded the examination of 
clinical outcome differences (ie, rejections, graft losses, 
death) between the 2 treatment groups. Our present findings 
of generally small to medium effects of adherence differ-
ences between treatment groups highlight the importance of 
sample size considerations for future study planning, as 
acquisition of larger samples allows for better detection of 
small to medium effects. Although our sample size was ade-
quate to reveal moderate to large associations between dos-
ing type and adherence (ie, dose adherence, timing adherence, 
and dichotomized pharmacy data), we had limited power to 
detect the significance of smaller effects seen for other mea-
sured variables. Nonetheless, examination of results for the 
other adherence measures suggests that, with the exception 
of self-report data, group differences seen with small to 
medium effect sizes for other adherence measures also con-
sistently favored once-daily dosing, supporting the reliability 
of the conclusions drawn herein. Future research with larger 
samples may be able to better determine whether inconsis-
tencies between adherence measures used here replicate and 
further clarify the utility of different adherence measures in 
predicting important health-related outcomes.
In relation to our sample, it is also notable that although 
our final sample included approximately 50% of those con-
tacted who met the inclusion criteria and were interested in 
participating in the study, many potentially eligible indi-
viduals were not interested in participating due to the length 
of the study and number of clinic visits involved, distance 
required to travel to the clinic, conflicts with other activi-
ties including work schedules, and worries about changing 
tacrolimus dosing schedule. As a result of this study’s 
exclusionary criteria and self-selection into the study, our 
sample may not be completely representative of the popula-
tion of renal transplant patients in Canada. It is possible that 
those who self-selected into the study differ in respect of 
some illness and demographic variables compared with 
their transplanted peers.
Conclusions
Our results provide support for replication of an advantage to 
once- versus twice-daily tacrolimus dosing among renal 
transplant recipients from a large urban transplant center in 
western Canada. To our knowledge, this is also the first study 
to extend previous findings using indices from pharmacy 
refill data in addition to electronically measured and self-
reported adherence. By showing an association between 
tacrolimus dosing and adherence with some measures of 
adherence, but not others, this study calls attention to the dif-
ferences observed between various measures of medication 
adherence used frequently in the literature. Importantly, this 
suggests that these measures may not necessarily be used 
interchangeably, and that more research is needed to better 
determine the predictive utility of different measures of 
adherence for specific health outcomes among renal trans-
plant recipients going forward.
With respect to future research, our results serve as a call 
to researchers to report effect sizes of analyses and to remain 
mindful of power and sample size considerations in the 
assessment of adherence. From a clinical standpoint, this 
study confirms the previously reported relationship between 
dose simplification and improved adherence in a Canadian 
sample of renal transplant recipients. This study also high-
lights important issues in the measurement of adherence that 
warrant consideration by prescribing practitioners and those 
monitoring adherence in this group. Future research would 
also benefit from the inclusion of patient-research partners in 
the study design to ensure feasibility, tolerability, and practi-
cality from the patients’ perspective on aspects such as num-
ber of visits, spacing between visits, and length of follow-up.
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